Cutaneous Oncology News

A smartphone app may help medical students more accurately differentiate melanomas from benign skin lesions, according to study results published in JAMA Dermatology.

Age should be a consideration when predicting response to immunotherapy for melanoma, according to study results published in Clinical Cancer Research.

The FDA approved cemiplimab-rwlc for IV treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma.

A review published in Annals of Internal Medicine found that although several treatment methods for basal cell carcinoma, including surgery, external beam radiation and topical creams, appear effective, evidence is too sparse to determine a best option between the interventions.

Active duty military members and veterans in the United States appear to be at elevated risk for melanoma and nonmelanoma skin cancers, according to study results published in Journal of the American Academy of Dermatology.

Immunotherapy agents — including ipilimumab, nivolumab and pembrolizumab — have changed the landscape of the treatment of advanced melanoma, resulting in 3-year survival rates of up to 58%.

B rian C. Capell , MD, PhD, received a Damon Runyon Clinical Investigator Award.

Regular use of sunscreen appeared associated with a reduced risk for melanoma among young adults in Australia, according to findings published in JAMA Dermatology.

Adverse skin reactions to anti-PD-1 therapy for cancer treatment can occur months after therapy initiation and even after patients discontinue treatment, study data showed.

People who used indoor tanning beds appeared more likely to check their skin for signs of cancer than those who did not tan, according to a research letter published in JAMA Dermatology.